ViiV's injection still suppresses HIV when taken every two m...

GSK’s ViiV Healthcare joint venture has announced data backing an injection taken that can suppress the HIV virus even if it is taken only six times a year, instead of every month.

FDA okays Nabriva’s novel antibiotic Xenleta for pneumonia

AZ's Farxiga first in class to improve outcomes in heart fai...

AstraZeneca has scored a major trial victory after its Farxiga (dapagliflozin) became the first drug in its class to show efficacy in heart failure, in patients with or without type-2 diabe

Fallout over Zolgensma data scandal continues for Novartis

Pharming buys rare disease drug from Novartis for $20m

Pharming has bought a late-stage pipeline drug aimed at a rare disease of the immune system from Novartis for $20 million up front, plus other payments further down the line.

First effective Ebola treatment a step closer after breakthr...

Clinical trials of four experimental treatments for Ebola in the Congo have been halted early after two of the drugs showed compelling benefits in a breakthrough against the deadly virus.